AT144185B - Process for the preparation of non-flocculent solutions of proteinaceous medicinal products. - Google Patents
Process for the preparation of non-flocculent solutions of proteinaceous medicinal products.Info
- Publication number
- AT144185B AT144185B AT144185DA AT144185B AT 144185 B AT144185 B AT 144185B AT 144185D A AT144185D A AT 144185DA AT 144185 B AT144185 B AT 144185B
- Authority
- AT
- Austria
- Prior art keywords
- preparation
- solutions
- proteinaceous
- medicinal products
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Darstellung niehtfloekender Lösungen eiweisshaltiger Heilmittel.
Bekanntlich zeigen eiweisshaltige Lösungen die Eigenschaft, dass sie nicht dauernd klar bleiben. sondern zur Flockenbildung neigen, was auf Denaturierung des Eiweisses beruht. Dieser Umstand macht sich besonders bei therapeutischen Präparaten störend bemerkbar.
Es wurde nun gefunden, dass man die Flockung von eiweisshaltigen Lösungen von Heilmitteln aufheben oder weitgehend verhindern kann. indem man den eiweisshaltigen Lösungen höhermolekulare Eiweissabbauprodukte, insbesondere Säuren, wie Protalbinsäure. Lysalbinsäure usw. zugibt. Insbesondere sind die Salze dieser Eiweissabbauprodukte, besonders die Alkalisalze, wie z. B. die Natrium-oder Kalium-
EMI1.1
Stoffe den fertigen Lösungen zugibt. Mit gleichem Erfolge können die die Flockung verhindernden Stoffe auch in einer beliebigen Stufe des Fabrikationsprozesses der eiweisshaltigen Lösung zugesetzt werden.
Als eiweisshaltige Heilmittel kommen beispielsweise die Absonderungsprodukte von Drüsen in Frage, ferner Serumeiweissstoffe oder Eiweisskörper aus Krebsgeweben. Als höhermolekulare Abbauprodukte können verwendet werden Spaltprodukte, erhalten durch alkalischen Abbau des Eiweisses. ferner Peptone. erhalten durch enzymatischen Abbau, z. B. durch Pepsinabbau.
Beispiele :
EMI1.2
etwa 1% protalbinsaurem Natrium unter Umrühren versetzt. Die Lösung zeigt nach dem Filtrieren keine Flockenbildung mehr.
2. Eine fraktionierte Thyreoglobin-Lösung wird auf die gewünschte Konzentration eingestellt und mit soviel protalbinsaurem Natrium versetzt, dass die Lösung etwa 10/00 davon enthält. Die Lösung wird nunmehr mit Trikresol sterilisiert und durch Seitzfilter geklärt.
3. Trockenpulver von Insulin wird nach dem Ergebnis der Standardisierung mit Alkali-bzw.
Natriumalbuminat vermischt und die Substanz allmählich in der berechneten Menge sauren Wassers aufgelöst, so dass eine an Alkalialbuminat etwa 1#ige Lösung entsteht. Nach dem Filtrieren erhält man eine beständige, keine Flocken bildende Lösung.
**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.
<Desc / Clms Page number 1>
Process for the preparation of non-flowing solutions of therapeutic products containing proteins.
It is well known that solutions containing proteins have the property that they do not remain clear all the time. but tend to form flakes, which is based on denaturation of the protein. This fact is particularly noticeable with therapeutic preparations.
It has now been found that the flocculation of protein-containing solutions of medicinal products can be eliminated or largely prevented. by adding higher molecular weight protein degradation products, in particular acids such as protalbic acid, to the protein-containing solutions. Lysalbinic acid, etc. adds. In particular, the salts of these protein degradation products, especially the alkali salts, such as. B. the sodium or potassium
EMI1.1
Adding substances to the finished solutions. The substances preventing flocculation can also be added to the protein-containing solution at any stage of the manufacturing process with the same success.
As protein-containing remedies, for example, the secretion products of glands come into question, as well as serum proteins or protein bodies from cancerous tissues. Cleavage products obtained by alkaline degradation of the protein can be used as higher molecular weight degradation products. also peptones. obtained by enzymatic degradation, e.g. B. by pepsin degradation.
Examples:
EMI1.2
about 1% sodium protalbinate is added while stirring. After filtering, the solution no longer shows any flake formation.
2. A fractionated thyroglobin solution is adjusted to the desired concentration and so much protalbinate sodium is added that the solution contains about 10/00 of it. The solution is now sterilized with tricresol and clarified through a Seitz filter.
3. Dry powder of insulin is according to the result of the standardization with alkali or.
Sodium albuminate mixed and the substance gradually dissolved in the calculated amount of acidic water, so that a solution of about 1 # of alkali albuminate is formed. After filtering, a stable, non-flaky solution is obtained.
** WARNING ** End of DESC field may overlap beginning of CLMS **.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE144185X | 1933-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AT144185B true AT144185B (en) | 1935-12-27 |
Family
ID=5670089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT144185D AT144185B (en) | 1933-07-08 | 1934-06-28 | Process for the preparation of non-flocculent solutions of proteinaceous medicinal products. |
Country Status (1)
Country | Link |
---|---|
AT (1) | AT144185B (en) |
-
1934
- 1934-06-28 AT AT144185D patent/AT144185B/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT144185B (en) | Process for the preparation of non-flocculent solutions of proteinaceous medicinal products. | |
DE651434C (en) | Method of preventing denaturation of protein medicinal products dissolved in water | |
CH178361A (en) | Process for the preparation of non-flocculent solutions of therapeutic products containing proteins. | |
DE464674C (en) | Process for the preparation of products containing cholesterol which are colloidally soluble in an alkaline medium | |
DE505062C (en) | Process for the production of drugs for organ or. tissue-specific treatment of diseases of the human and animal body | |
DE694100C (en) | Process for the production of metal compounds | |
DE940133C (en) | Process for obtaining highly effective organ extracts | |
AT117834B (en) | Process for increasing the baking quality of flours. | |
DE385309C (en) | Process for the production of essences | |
DE604070C (en) | Process for the production of neutral soluble complex salts of trivalent antimony | |
DE629841C (en) | Process for the preparation of an aqueous quinine solution for injection purposes | |
DE520225C (en) | Process for the production of a condensation product | |
DE373986C (en) | Process for the production of tooth root fillings | |
DE749861C (en) | Process for making tasty food | |
DE874061C (en) | Process for the production of a blood-coagulant substance from the lungs | |
DE571404C (en) | Process for removing proteins from liquids, e.g. B. Sera | |
AT146967B (en) | Process for the production of heavy metal compounds of the porphine series. | |
DE335063C (en) | Process for the production of phosphorus-containing silica-protein compounds | |
DE723530C (en) | Process for the enrichment of gonadotropic agents | |
DE513205C (en) | Process for the preparation of derivatives of the aminoarylantimony compounds | |
DE478167C (en) | Process for obtaining permanently soluble and durable preparations with increased therapeutic effectiveness in water from proteins or their derivatives (cleavage products) | |
DE646595C (en) | Process for making a laxative | |
DE556144C (en) | Process for the preparation of complex gold nucleic acid compounds | |
AT66592B (en) | Process for the production of iron-milk and soluble iron-milk preparations which, in addition to iron in masked form, also contain glycerol phosphoric acid, intimately bound to genuine milk protein. | |
DE655684C (en) | Process for the production of metal compounds of keratinic acids |